Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy--C...
Source: businessinsider.com